Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PoltregWAR:PTG -0.51%42 EBIT per Share is zł-5.48 as of Mar. 2026. GuruFocus rates WAR:PTG with a GF Score™ of 42/100 and a GF Value™ of zł14.20 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,173 Biotechnology companies, Poltreg ranks worse than 96.68% on this metric.
Poltreg's EBIT per Share for the
three
months ended in Mar. 2026 was zł-1.41.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł-5.48.
During the past 3 years, the average EBIT per Share Growth Rate was -71.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -77.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Poltreg's EBIT per Share or its related term are showing as below:
WAR:PTG'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -129.1 Med: -71.1 Max: -39.2
Current: -71.1
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Poltreg was -39.20% per year. The lowest was -129.10% per year. And the median was -71.10% per year.
WAR:PTG's 3-Year EBIT Growth Rate is ranked worse than 96.68% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs WAR:PTG: -71.10
Poltreg's EBIT for the
three
months ended in Mar. 2026 was zł-6.58 Mil.
Poltreg (WAR:PTG) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Poltreg EBIT per Share Related Terms
Poltreg EBIT per Share Historical Data
* Premium members only.
The historical data trend for Poltreg's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-5.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poltreg (WAR:PTG) has a EBIT per Share of zł-5.48 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Poltreg and its competitors. According to the industry distribution chart, Poltreg ranks #1134 out of 1173 companies in the Biotechnology industry, placing it in the top 96.7%.
Is Poltreg's EBIT per Share too high?
Poltreg's current EBIT per Share is zł-5.48. Based on the distribution chart, Poltreg ranks #1134 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Poltreg has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Poltreg's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poltreg ranks #1134 out of 1173 companies for EBIT per Share. This places Poltreg in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Poltreg and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poltreg's current EBIT per Share is zł-5.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poltreg stock overvalued right now?
Based on GuruFocus' analysis, Poltreg (WAR:PTG) is currently considered Significantly Overvalued. The stock's GF Value™ is zł14.20, compared to a current price of zł19.60 — trading 38% above its estimated fair value. The current EBIT per Share is zł-5.48. Poltreg's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Poltreg (WAR:PTG), the current EBIT per Share is zł-5.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poltreg (WAR:PTG) Overvalued in 2026?
Based on GuruFocus' analysis, Poltreg stock appears to be overvalued.
The current stock price of zł19.60 is trading 38% above its estimated GF Value™ of zł14.20.
GuruFocus considers Poltreg to be Significantly Overvalued.
Key valuation signals for WAR:PTG:
EBIT per Share: zł-5.48
GF Value™: zł14.20 vs. price of zł19.60 (38% above fair value)
No single metric tells the full story. See the WAR:PTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poltreg SA is a biotechnology company at the clinical stage developing an innovative generation of medicines using T-regulatory cells (TREGS) in the treatment of autoimmune diseases.
42GF Score
Get the complete analysis for WAR:PTG
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:PTG has been successfully added to your 
